LONDON and BOSTON, March 22,
2022 /PRNewswire/ -- Hikma Pharmaceuticals PLC
(Hikma), the multinational pharmaceutical company, today announced
that its venture capital arm, Hikma Ventures has led an
$15 million USD round of financing
for Activ Surgical, a pioneering digital surgery imaging startup
that is developing groundbreaking interoperative surgical
intelligence hardware and software. The investment is an extension
of the Series B round that was previously announced by Activ
Surgical in September 2021. This most
recent financing, which also saw participation from existing
investors, brings the total Series B round to $60 million USD.
Activ Surgical aims to revolutionize access to surgical care,
enabling a future of augmented reality (AR)-based and artificial
intelligence (AI)-driven surgery that is safe, smart, and
accessible to all. The company's patent-protected surgical
intelligence platform – ActivEdge™ – is being designed to reduce
unintended and preventable surgical errors by enhancing a surgeon's
interoperative decision-making through the use of AI. Activ
Surgical's first product — the ActivSight™ imaging module —
seamlessly upgrades existing operating room equipment, serving as
the "eyes" of the ActivEdge platform. It allows surgeons to access
critical intraoperative visual data as AR overlays. In 2021, the
ActivSight imaging module was cleared by the FDA and
successfully used in its first-in-human studies. To date, multiple
major hospital networks across the U.S. and Europe have been established as pilot sites.
The ActivSight imaging module is available now via a limited market
release and will be broadly available in 2022.
"Hikma Ventures' investment in Activ Surgical comes at a
critical inflection point in the company's history as our team is
hard at work preparing for the global launch of our ActivSight
imaging module later this year," said Todd
Usen, CEO, Activ Surgical. "This investment will allow us to
scale our business quickly and add resources needed to ensure a
successful rollout of the ActivSight imaging module, helping to
fulfil our mission to empower surgeons' intraoperative
decision-making and, ultimately, enhance patient safety. Hikma's
position in the global healthcare landscape helps validate our
mission to provide better patient outcomes globally."
"We are thrilled to invest in Activ Surgical and support their
mission to democratize surgical care and to eliminate unintended
surgical complications to improve patient outcomes and empower
surgeons across the globe," said Lana
Ghanem, Managing Director of Hikma Ventures. "This is the
latest example of Hikma Ventures' commitment to supporting
pioneering companies utilizing cutting-edge technologies to
meaningfully improve patients' lives. We look forward to working
with the talented Activ Surgical team to help them expand the
global reach of their innovative platform to different geographies,
especially the Middle East."
Investor
Enquiries:
|
|
Hikma
Ventures
|
|
Lana Ghanem
|
lana@hikmaventures.com
|
Managing Director,
Hikma Ventures
|
+962 6 580
3100
|
|
|
Media:
|
|
Steve Weiss
|
+1 732 788
8279
|
David Belian
|
+1 848 254
4875
|
US Communications and
Public Affairs
|
uscommunications@hikma.com
|
|
|
U.S. Media Conact
for Activ Surgical:
|
|
Heath Meyer
(heath@teamseismic.com / 858-768-1527)
|
|
About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC:
HKMPY) (rated BBB-/stable S&P and BBB-/stable Fitch)
Hikma helps put better health within reach every day for millions
of people around the world. For more than 40 years, we've been
creating high-quality medicines and making them accessible to the
people who need them. Headquartered in the UK, we are a global
company with a local presence across the
United States (US), the Middle
East and North Africa
(MENA) and Europe, and we use our
unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,600 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner,
and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more
information, please visit: www.hikma.com
About Hikma Ventures
Founded in August 2015, Hikma Ventures operates as the
corporate venture capital arm of Hikma Pharmaceuticals. Hikma
Ventures invests in global start-ups where Hikma's expertise can
accelerate revenue growth and enhance value creation by providing
ventures with access to the resources of a multinational
pharmaceutical company. For more information, please visit
www.hikmaventures.com.
About Activ Surgical
Activ Surgical is the pioneering digital surgery company that
completed the world's first autonomous robotic surgery of soft
tissue in 2018. The company is revolutionizing surgical vision,
enabling a future of augmented reality-based and artificial
intelligence-driven surgery that is safe, smart, and accessible to
all. Its patent-protected surgical software
platform--ActivEdge™--is being designed to reduce unintended and
preventable surgical errors by enhancing a surgeon's intraoperative
decision making via the aggregation of surgical data from around
the world. Activ Surgical is privately held, and backed by Hikma
Ventures, DNS Capital, Cota Capital, BAM Funds, GreatPoint
Ventures (GPV), ARTIS Ventures, LRVHealth, Tao Capital Partners,
Magnetar Capital, NVIDIA, Rising Tide VC, MINT Venture Partners,
Castor Ventures, SONY Innovation Fund, and Dream One Vision. Learn
more at www.activsurgical.com.
View original
content:https://www.prnewswire.com/news-releases/hikma-ventures-leads-series-b-extension-in-activ-surgical-to-support-the-global-commercialization-of-its-platform-301507575.html
SOURCE Hikma Pharmaceuticals USA Inc.